Chinese mobile companies making more in India to dim regulatory glare
Chinese smartphone companies are now outsourcing production to Indian firms like Dixon Technologies. This follows a possible push from the Indian government. Brands are shifting manufacturing risks and aiming for cost reduction. Oppo's factory shipments have decreased due to outsourcing. Dixon anticipates significant smartphone production growth. Joint ventures and strategic partnerships are also emerging in the sector.
Tired of too many ads?
Remove Ads
Tired of too many ads?
Remove Ads
Chinese smartphone brands are increasingly outsourcing production to Indian contract manufacturers , benefiting the likes of Dixon Technologies and Bhagwati Products (Micromax), following what industry executives see as an unofficial nudge from government.Despite having excess capacities in their own manufacturing facilities in India, Chinese smartphone brands are outsourcing a large part of production to companies that are participants in the government's production-linked incentive scheme , industry executives and market trackers said.Brands are not just outsourcing volumes, but also shifting the risk of government interventions and scrutiny, they said.They are on course to become more asset-light in India, where they face a tough regulatory environment. Offloading manufacturing - which incurs huge capital and operating expenses and has additional compliance issues - helps in cutting costs at a time when they are facing a liquidity crisis and stressed balance sheets, executives aware of the development told ET.According to Counterpoint Research, Oppo's shipments from its Noida factory fell 34% on-year in 2024 due to the increasing contribution of outsourced manufacturing by Dixon Technologies and Bhagwati Products.At a recent earnings call, Dixon Technologies chief executive Atul Lall projected the sales volume in India's smartphone market to be around 150 million a year. "Out of that 150-odd million, Android space is around 135-140 million. Various brands are manufacturing in-house. And the outsourcing opportunity is around 90 million. And including our new tie up of Vivo, we are targeting for around 60-65 million by next year," he said.Dixon made 28.3 million smartphones in fiscal 2025. Its projection for the this fiscal year is 43-44 million.Lall said Dixon will be manufacturing 7-8 million smartphones for Realme (an Oppo subsidiary), which will be expanded in the next few years. It will also be supplying around 15-16 million smartphones to Vivo in January-March quarter of 2026, by when it expects to get government approvals for its joint venture with the Chinese company.Brands such as Transsion and Vivo have also signed strategic partnerships with Dixon to form joint ventures where the volumes and revenues are split between the two partners."For Chinese companies, there seems to be an informal diktat from the government of India encouraging them to have some part of their volumes manufactured by Indian players. This is happening even though these companies have significant unutilised in-house manufacturing capacity," an industry executive who did not wish to be named told ET. Samsung, Oppo and Vivo each have around 60 million units of capacity in India, while their annual sales are around 20-25 million, market trackers said.Emailed queries to Oppo and Bhagwati didn't elicit any response till press time Tuesday."Given the low margins in assembly, to have a positive unit economics you need a large scale, which is there with EMS (electronics manufacturing services) players like us. You can only achieve so much scale with making for your own brand. The trend of in-house manufacturing moving towards outsourcing, it's primarily to deleverage their balance sheets," Lall told ET.Another industry executive told ET that Chinese brands are choosing to make only their high-end and flagship models in-house, outsourcing the entry-level models to Indian contract manufacturers.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
42 minutes ago
- Hindustan Times
Housing sales decline 20% in India, 25% in MMR
Mumbai: Increasing property prices and geopolitical tensions across the world have hit housing sales in seven metropolitan cities in India, with sales dropping by 20% in the second quarter of 2025 compared to the second quarter of 2024. The Mumbai Metropolitan Region (MMR) was hit the hardest, with housing sales dropping by 25%, from 41,540 units in the second quarter of 2024 to 31,275 units in the second quarter of 2025, according to a report by real estate consulting firm, Anarock. (Hindustan Times) Approximately 96,285 houses were sold in the second quarter (April-June) of 2025 across the seven metropolitan cities – National Capital Region, MMR, Bengaluru, Pune, Hyderabad, Chennai and Kolkata, compared to 120,335 houses sold in the same period in 2024. Housing sales in the seven cities increased marginally by 3% compared to the first quarter of 2025, the report shows. Chennai, the National Capital Region (NCR), Hyderabad and Bengaluru witnessed a spike in sales by 40%, 14%, 9% and 1% respectively. But in Kolkata, Pune and the MMR, housing sales dropped by 10%, 4% and 1%, respectively. 'The second quarter of 2025 was a rollercoaster for the Indian housing market, rocked by major military actions at home and abroad. The war-like climate pushed homebuyers into wait and watch mode, compounding the impact of soaring property prices over the past two years,' Anuj Puri, chairman, Anarock Group, told Hindustan Times. 'Now, with domestic tensions easing and the Reserve Bank of India's repo rate cut injecting fresh optimism, buyer sentiment is rebounding.' Similar sentiments were shared by other real estate consultants. 'Geopolitical tensions always have an impact on Indian real estate, though the degree varies depending on the geography and Indian economic interests in those countries,' said a real estate consultant, requesting anonymity. 'This time around, with America intervening in the Iran-Israel war, people feared that a medium to large-scale conflict may lead to economic slowdown or job cuts. Hence, home hunters decided to keep their purchase decisions on hold.' In keeping with the dip in sales, new launches decelerated by 16% on a year-on-year basis, from approximately 117,165 units in the second quarter of 2024 to around 98,625 units in the second quarter of 2025. Realty hotspots MMR and NCR saw the maximum new supply, accounting for 48% of the total new supply across the seven cities. MMR witnessed a 36% yearly decline and a 8% quarterly decline in new supply. One of the top developers in the MMR, who recently launched a project in the extended Navi Mumbai area, said, 'When the Ukraine-Russia conflict broke out in February 2022, we thought it would last only a few weeks, but we have been proved wrong. But that conflict did not have as much impact on India's realty industry as the one in the Middle East, especially with America's involvement.' Puri was optimistic about an uptick in sales in forthcoming quarters. 'Despite a 20% year-on-year dip in sales across the top seven cities, a 3% uptick this quarter signals renewed momentum,' he said. 'With home loan rates softening and developers largely holding prices steady, the stage is set for a potential upswing in housing sales in the coming quarters.'
Time of India
an hour ago
- Time of India
Torrent Pharma to acquire JB Chemicals at Rs 25,689 crore valuation
Torrent Pharma will acquire a controlling stake in JB Chemicals from KKR. The deal values JB Chemicals at Rs 25,689 crore. This merger will elevate Torrent to fifth position in the Indian pharmaceutical market. KKR is expected to gain a fivefold return on its 2020 investment. The combined entity aims for significant revenue and profitability growth. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Ahmedabad-based drugmaker Torrent Pharma has agreed to buy a controlling stake in JB Chemicals from global private equity firm KKR at an equity valuation of Rs 25,689 crore ($3 billion). The deal, which will see a merger of the two entities, is among the biggest in the Indian pharmaceutical sector and brings to an end year-long negotiations. They had come close to a deal last year but couldn't agree on valuation at the the acquisition of JB Chemicals, Torrent will move up to fifth rank by market share in the $26 billion Indian pharmaceutical market ahead of Alkem and Intas Pharma. ET had on June 29 been the first to report on the merger deal was announced following a marathon meeting of Torrent Pharma's board of directors on against the stock's Friday close of Rs 1,792. Torrent will also acquire up to 2.8% equity from certain employees of JB Chemicals at the Rs 1,600 apiece. The second part of the deal will follow amerger between Torrent and JB Chemicals through a scheme of arrangement. As per the approval by the two boards, upon the merger, every shareholder holding 100 shares in JB Chemicals will get 51 shares of Torrent. KKR had been the first to seek a restart of negotiations, according to the people cited above. Even at the discounted price, it will end with a fivefold return on what it paid to acquire JB Chemicals in Pharma posted FY25 revenue of Rs 11,500 crore, of which the Indian market accounted for Rs 6,393 crore. JB Chemicals recorded total FY25 sales of Rs 3,918 crore, of which the Indian market accounted for Rs 2,269 crore, growing at 20% over the previous the last decade, Torrent has grown inorganically with a string of deals that included skincare drugs maker Curatio in 2022 and more recently a range of anti-diabetes drugs from Boehringer Ingelheim. Apress statement from Torrent Pharma said the transaction marks a significant step in its ambition to create a future-ready, diversified healthcare platform combining a deep chronic segment heritage with emerging international CDMO (contract development and manufacturing) capabilities. The deal is a strong fit for Torrent and complements its India presence, helping it move into the promising field of contract manufacturing besides allowing for market synergy, an analyst said. 'Torrent has a proven record of making deals work successfully,' the person company will get access to leading brands in the chronic segment and entry into untapped therapeutic areas such as ophthalmology. Torrent said it will derive operational synergies across multiple business functions. 'We are pleased to have on board the JB Chemicals heritage and build on the platform for the future,' said Torrent Pharma executive chairman Samir Mehta. 'Torrent's deep India presence and JB Chemicals' fast-growing India business, combined with the CDMO and international footprint offers immense potential to scale both revenue and profitability.'For KKR, this follows strong investment activity in India, where the buyout group has deployed more than $2 billion in private equity investments in the past year alone, in addition to a recent $600 million financing of Manipal Group. This also builds on KKR's strong healthcare track record, including a fivefold return in Max Healthcare in 2022 that had also marked the largest block deal by a private equity firm in India, and recent investments in healthcare, including Healthcare Global Enterprises, BMH (Baby Memorial Hospital), Healthium and Chemicals said it had built a strong foundation to deliver market-leading growth, as well as consistent improvement in profitability in the medium and long term. 'As we now enter a new chapter alongside Torrent Pharmaceuticals, we are confident that the combined strengths of our organizations will unlock greater opportunities to enhance healthcare access across our markets,' said Nikhil Chopra, chief executive officer and whole time director of JB Chemicals.
Time of India
an hour ago
- Time of India
Torrent Pharma to Acquire JB Chemicals at ₹25k cr Valuation
Ahmedabad-based drugmaker Torrent Pharma has agreed to buy a controlling stake in JB Chemicals from global private equity firm KKR at an equity valuation of ₹25,689 crore ($3 billion). The deal, which will see a merger of the two entities, is among the biggest in the Indian pharmaceutical sector and brings to an end year-long negotiations. They had come close to a deal last year but couldn't agree on valuation at the time. With the acquisition of JB Chemicals, Torrent will move up to fifth rank by market share in the $26 billion Indian pharmaceutical market ahead of Alkem and Intas Pharma. ET had on June 29 been the first to report on the merger details. The deal was announced following a marathon meeting of Torrent Pharma's board of directors on Sunday. That's against the stock's Friday close of ₹1,792. Torrent will also acquire up to 2.8% equity from certain employees of JB Chemicals at the Rs 1,600 apiece. The second part of the deal will follow a merger between Torrent and JB Chemicals through a scheme of arrangement. As per the approval by the two boards, upon the merger, every shareholder holding 100 shares in JB Chemicals will get 51 shares of Torrent. KKR had been the first to seek a restart of negotiations, according to the people cited above. Even at the discounted price, it will end with a fivefold return on what it paid to acquire JB Chemicals in 2020. Torrent Pharma posted FY25 revenue of ₹ 11,500 crore, of which the Indian market accounted for Rs 6,393 crore. JB Chemicals recorded total FY25 sales of Rs 3,918 crore, of which the Indian market accounted for Rs 2,269 crore, growing at 20% over the previous year. Over the last decade, Torrent has grown inorganically with a string of deals that included skincare drugs maker Curatio in 2022 and more recently a range of anti-diabetes drugs from Boehringer Ingelheim. A press statement from Torrent Pharma said the transaction marks a significant step in its ambition to create a future-ready, diversified healthcare platform combining a deep chronic segment heritage with emerging international CDMO (contract development and manufacturing) capabilities. The deal is a strong fit for Torrent and complements its India presence, helping it move into the promising field of contract manufacturing besides allowing for market synergy, an analyst said. 'Torrent has a proven record of making deals work successfully,' the person added. The company will get access to leading brands in the chronic segment and entry into untapped therapeutic areas such as ophthalmology. Torrent said it will derive operational synergies across multiple business functions. 'We are pleased to have on board the JB Chemicals heritage and build on the platform for the future,' said Torrent Pharma executive chairman Samir Mehta. 'Torrent's deep India presence and JB Chemicals' fast-growing India business, combined with the CDMO and international footprint offers immense potential to scale both revenue and profitability.' For KKR, this follows strong investment activity in India, where the buyout group has deployed more than $2 billion in private equity investments in the past year alone, in addition to a recent $600 million financing of Manipal Group. This also builds on KKR's strong healthcare track record, including a fivefold return in Max Healthcare in 2022 that had also marked the largest block deal by a private equity firm in India, and recent investments in healthcare, including Healthcare Global Enterprises, BMH (Baby Memorial Hospital), Healthium and Infinx. JB Chemicals said it had built a strong foundation to deliver market-leading growth, as well as consistent improvement in profitability in the medium and long term. 'As we now enter a new chapter alongside Torrent Pharmaceuticals, we are confident that the combined strengths of our organizations will unlock greater opportunities to enhance healthcare access across our markets,' said Nikhil Chopra, chief executive officer and whole time director of JB Chemicals.
